Form 8-K - Current report:
SEC Accession No. 0001193125-24-268003
Filing Date
2024-11-29
Accepted
2024-11-29 14:33:53
Documents
15
Period of Report
2024-11-27
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d816234d8k.htm   iXBRL 8-K 27714
2 EX-99.1 d816234dex991.htm EX-99.1 15836
6 GRAPHIC g816234dsp1a.jpg GRAPHIC 3997
  Complete submission text file 0001193125-24-268003.txt   175005

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fate-20241127.xsd EX-101.SCH 2879
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fate-20241127_lab.xml EX-101.LAB 17237
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fate-20241127_pre.xml EX-101.PRE 10832
18 EXTRACTED XBRL INSTANCE DOCUMENT d816234d8k_htm.xml XML 3541
Mailing Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131
Business Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

EIN.: 651311552 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36076 | Film No.: 241515974
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)